Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation

Exp Hematol. 2001 Mar;29(3):362-70. doi: 10.1016/s0301-472x(00)00655-x.

Abstract

Objective: Matched unrelated bone marrow transplantation (BMT) for patients with hematological malignancies is associated with a high incidence of transplant-related complications due to high doses of chemoradiotherapy administered pre-BMT to ensure engraftment. The aim of this study was to investigate the feasibility of low-intensity conditioning for BMT from matched unrelated donors.

Materials and methods: Sixteen patients with hematologic malignancies underwent non-T-cell-depleted BMT following a low-intensity conditioning regimen consisting of fludarabine monophosphate 30 mg/m(2)/day for 6 days, busulfan 4 mg/kg/day for 2 days, anti-T lymphocyte globulin 10 mg/kg/day for 4 days. Seven of the patients suffered from chronic myelogenous leukemia, four from acute lymphoblastic leukemia, four from acute myelogenous leukemia, and one from Ki-1 non-Hodgkin's lymphoma. Three of the patients had secondary leukemia and two were post-autologous BMT (ABMT). All patients were transplanted from fully matched unrelated donors.

Results: Fifteen of the 16 patients had 100% donor chimerism; no graft rejection was observed. None of the patients developed >Grade II veno-occlusive disease, sepsis, multiorgan failure, or renal or pulmonary toxicity. Four patients died posttransplant; one of thrombocytopenia and severe hemorrhagic cystitis, one of central nervous system toxicity, one of Grade IV graft-vs-host disease, and one following relapse (9 months post-BMT). Survival and disease-free survival at 36 months are 75% (95% confidence interval 46-90%) and 60% (95% confidence interval 30-80%), respectively.

Conclusion: These results indicate that low-intensity conditioning is sufficient to ensure stable engraftment of bone marrow grafts in a matched unrelated setting.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antilymphocyte Serum / administration & dosage*
  • Bone Marrow Transplantation / adverse effects
  • Bone Marrow Transplantation / methods*
  • Bone Marrow Transplantation / mortality
  • Busulfan / administration & dosage*
  • Cell Count
  • Child
  • Cohort Studies
  • Disease-Free Survival
  • Female
  • Graft Survival
  • Histocompatibility
  • Humans
  • Leukemia / mortality
  • Leukemia / therapy
  • Life Tables
  • Lymphoma, Large-Cell, Anaplastic / therapy
  • Male
  • Middle Aged
  • Recurrence
  • Survival Analysis
  • T-Lymphocytes
  • Transplantation Conditioning / adverse effects
  • Transplantation Conditioning / methods*
  • Transplantation, Homologous / adverse effects
  • Transplantation, Homologous / methods*
  • Transplantation, Homologous / mortality
  • Treatment Outcome
  • Vidarabine / administration & dosage*
  • Vidarabine / analogs & derivatives*

Substances

  • Antilymphocyte Serum
  • Vidarabine
  • Busulfan
  • fludarabine